Homepage
Author:
Knight Therapeutics
Posted Date:
March 27, 2026
Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity
Knight Therapeutics
March 27, 2026
Knight Amends Normal Course Issuer Bid
Knight Therapeutics
March 23, 2026
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Knight Therapeutics
March 19, 2026
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
Knight Therapeutics
March 17, 2026
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Knight Therapeutics
March 17, 2026
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call
Knight Therapeutics
March 12, 2026
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
Knight Therapeutics
February 18, 2026